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Ebola is one of the members of filoviruses family. It causes severe hemorrhagic with the human mortality 
rate of 50-90%. In the initial steps of infection, it enters the host cell by Glyco protein1 (GP1). GP1 is a big 
subunit with the molecular weight of 130 kDa. Its N-terminal domain is responsible for attaching the host 
cell. In the present study, a database containing 100.000 drug like chemicals which was obtained from Zinc 
has been screened. The top successive hits were then analyzed regarding Lipinski rules, oral toxicity value 
and recorded biological properties. Finally, 3 new ligands were introduced as new theoretical inhibitors of 
Ebola virus entry. Hit #1 (Heptacyclo[18.7.0.02,10.03,8.011,19.012,17.021,26] 
heptacosa1(20),2(10),3,5,7,11(19),12,14,16,21,23,25-didecaene-9,18,27-trione) indicated the binding 
affinity of -10.7 kcal/mol with previous biological reports indicating no toxicity on human cell line. Hit#3 
(1,1',3,3'-tetraethyl-5'-(4-nitrophenyl)spiro[1,3-diazinane-5,6'-5H-furo[2,3-d]pyrimidine]-2,2',4,4',6 
pentone) with the binding affinity of -9.7 kcal/mol theoretically passed pharmacological filters and the 
toxicity class of 4 theoretically revealed that this hit also can be a potential anti GP1 agent. Moreover, 
hit#4(10-(Hydroxymethyl)-7,18-dimethoxy-6,17-dimethyl-21-methyl-11.21     
diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),6,15(20),17-tetraene-5,8,12,16,19-pentone) also 
indicated the binding affinity of -9.7 kcal/mol and was matched with Lipinski rules and the toxicity class 4, 
suggesting that it can be safe in low dose usage. Based on the pharmacological properties, hit #1, 3 and 4 
are presented as the new hypothetical drugs against GP1. Moreover, hit#1 has previously been recorded as 
nontoxic activity on human cell line and makes it an appropriate candidate for further in vitro and in vivo 
studies. 
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INTRODUCTION 
     Ebola virus is one of two family members’ 
filoviruses which causes severe hemorrhagic 
fever with a human fatality of 50-90%. There is 
not any vaccine or cure yet existing in 
combination with frequent appearance of this 
virus, and its high spread among wildlife; ease of 
importing viruses into the cell has made it an 
important public health concern. Ebola virus 
(EBOV) creates Ebola disease (EVD), a disease 
with a high mortality rate that is died more than 
11000 people from February to December 1, 
2014 as   reported by Centers for Disease Control 
and Prevention 2014. Gomes et al reportage was 
the first published report of the risk assessment 
[1]. Recently, 1500 genomes of Ebola virus have 
been studied from several patients: the results and 
data of the respected author teams are attainable 
free of the charge on scientific databases [2]. 
Import and virus entry into cells is mediated by a 
glycoprotein (GP), the virion surface glycoprotein 
[3]. GP is known as class I fusion protein [4, 5] 
which ligates to the cell surface and fuses with an 
inner membrane of the cell. Like many other class 
I fusion proteins such as influenza virus 
hemagglutinin, intact GP trimer of heterodimers 
consist of a subunit ligating to the receptor (GP1) 
and a fusion subunit (GP2) [6]. Two subunits are 
produced through cleavage of a pre-protein as GP 
via the Golgi compartment and stay via a 




disulfide bond and non-covalent interactions. GP1 
is a big subunit (definite molecular mass of 130 
kDa) that contains a cap including 4 N-linked 
carbohydrate addition sites and a large domain 
that is O-glycosylated which is a mucin-like 
domain. The mucin-like domain is inessential for 
infection of cells in culture medium; 
pseudovirions and virus - like particles with their 
mucin-like domain (GP) is deleted by genetic 
engineering techniques and are absolutely 
qualified for entry and infection [7-9]. The two 
carbohydrate substance motifs of GP1 are located 
on a top domain, which includes a receptor 
binding region (RBR) [7, 8, 10-12]. In turn, the 
top of the GP1 is located on the head of a base 
that is widely interacting with fusion subunit 
(GP2), which makes a fusion ring [13]. 
Endosomal protease enzymes named cathepsin B 
(Cat B) and cathepsin L (cat L) are needed for 
Ebola virus to import to the cytoplasm and thus to 
infect host cells [8, 9, 14]. Cat B and Cat L 
proteases cut GP within misfolded 13-14 rings of 
GP1, producing an average of 20 kDa and then 
original and special 19 kDa core protein [7, 9, 
15]. It seems that the interaction produces an 
average 50-kDa protein that is similar to the GP. 
According to these great cutting events, GP2 is 
completely conserved and holds disulfide 
connected to the GP1. Production of 19 kDa GP 
deletes the mucin-like motif, glycans hat, and the 
outer string [16] of the top domain of GP1. The 
Receptor binding region (RBR) and backbone of 
GP1 and also GP2 are all kept native. In the 
previous study, a key protein of Ebola virus 
which has the important action in both virus 
assembly and budding functions was targeted. 
Prohibition of VP40 assembly excludes octamer 
structure foundation and disturbs a vital stage in 
the virus life cycle. A single VP40 construction in 
the biological situation was also targeted, and a 
drug model which prevents oligomerization of 
VP40 subunits was found; so the potential 
inhibitors for Ebola virus was predicted [17].  But 
in this study, according to the GP1 based 
mechanism of entry of Ebola virus into the host 
cell, we tried to find an appropriate ligand with 
acceptable pharmacological quality with the 
ability to bind GP1 and inhibit the virus entry to 
the host cell. 
 
MATERIALS AND METHODS 
Structures 
     Currently, there is not any crystallography 
structure available for GP1 from Ebola Virus. So 
its nature is predicted based on homology 
modeling. To do this, the sequence of Zaire Ebola 
virus (accession number: 965569707) for 
identification of homolog crystal templates was 
used. The modeling process followed by I-Tasser 
webserver(http://zhanglab.ccmb.med.umich.edu/I
-TASSER/); it was carried out using Chain I, 
Crystal Structure of Sudan Ebolavirus 
Glycoprotein (PDB ID: 3VE0) as the main 
template [18-20]. The predicted structure was 
checked by Prosa Z score for quality control [21]. 
The final structure was submitted to FindSite web 
server (www.cssb.biology.gatech.edu/finalsite) to 
find its potential binding sites [22, 23]. After 
identification of pockets, Zinc database was 
docked against the pockets and top 1000 ligands 
was extracted for further screening process [24].  
Selecting high-affinity ligands 
     In order to simulate biological conditions, the 
final predicted model was put into water box in 
the presence of neutralizing ions. The system was 
then minimized regarding energy level by 
GROMACS 4.5.6 simulation package [25]. The 
most important residues which are involved in 
receptor binding are first 150 N-Terminal domain 
residues. Subsequently, a radius of 20 Å along 
with coordinates of X: 73, Y: 97 and Z: 127 was 
applied to cover the entire area. Virtual screening 
was also performed by PyRx software [26, 27]. 
Analysis of pharmacological properties 
 Top successive hits were analyzed regarding 
pharmacological properties by FAF Drugs 3 
server [28] ; the unspecific bindings were also 
measured by PROTOX web server [29]. 
  
RESULTS  
  In the present study, the 3D structure of GP1 
was initially predicted and after structure 
verifications, a database containing 100.000 
ligands was screened and 4 hits were found which 
could potentially inhibit the viral entry by 
blocking the N-terminal domain of GP1. In order 
to reach high binding affinity poses, the virtual 
screening radius was put in the N-terminal 
domain of GP1. Top successive hits were filtered 




regarding Lipinski rule of 5 and finally 4 hits 
were selected for the further study. The structures 




with the molecular weight of 384.38238 g/mol, 
reaching a binding affinity of -10.7 kCal/mol. Its 
bio assay is reported by PubChem as inactive in 
NCI human tumor cell line growth inhibition 
bioassay. (Data for the NCI-H23 Non-Small Cell 
Lung cell line).  
 
Figure1. The structure of 4 successive hits which binds to the GP1 from Ebola virus, A: hit#1, B: hit#2, C: hit#3 and D: hit#4 
 
    Interestingly, this hit matches with the Lipinski 
rule of 5. The molecular formula (C27H12O3) 
indicates that its components are carbon and 
oxygen. Based on the ligand map of hit#1 which 
is depicted in figure 2a, it has several interactions 
with amino acids: Trp 13, Arg 14, Pro 16, Asn 
49, Lys 63, His 65, Leu 66 and Thr 68. The 
protox result of this hit predicted LD50 of 
385mg/kg with the toxicity class 4 and no toxicity 




enicosa-2(11),6,8,17-tetraen-12-one) could reach 
a binding affinity of -10.2 and has no record in 
the PubChem but matches with the Lipinski rule 
of 5. Its ligand map (figure 2b) indicates that it is 
in contact with amino acids: Trp 13, Arg 14, Pro 
15, Pro16, Asn 49, Asn 50, Lys 63, His 65 and 
Leu 66. The protox results indicated that although 
this hit matches Lipinski rules, but it has a 
predicted LD50 of 6mg/kg with the toxicity class 
of 2 and its pharmacophore has interference with 
Amine Oxidase A and Prostaglandin G/H 
Synthase 1. So this hit cannot be suggested as an 
anti-Ebola agent. Hit#3 (IUPAC name: 1,1',3,3'-
tetraethyl-5'-(4-nitrophenyl)spiro[1,3-diazinane-
5,6'-5H-furo[2,3-d]pyrimidine]-2,2',4,4',6-
pentone) does not have any biological assay 
record in PubChem but the protox results predicts 
that is has the toxicity class of 4 with the LD50 of 
500 mg/kg. Moreover, no toxicity target has been 
identified. The ligand map (figure 2c) indicates 
that it is in contact with amino acids: Arg 14, Pro 
15, Pro 16, Asn 18, Asn 49, Lys 63, Glu 64, His 
65, Leu 66, Ala 67 and Thr 68 which indicates 
that this hit covers amino acid position 63-68 
sequentially. This ligand can also be introduced 
as the new inhibitor of GP1 from Ebola Virus. 
This hit could reach the binding affinity of -9.7 
kcal/mol.  Hit#4 (IUPAC name: 10-
(Hydroxymethyl)-7,18-dimethoxy-6,17-dimethyl-
21-methyl-11.21- diazapentacyclo  
[11.7.1.02,11.04,9.015,20] henicosa-
4(9),6,15(20),17-tetraene-5,8,12,16,19-pentone) 
also indicates that the binding affinity of -9.7 




does not have any recorded biological properties 
in PubChem. Its LD50 of 445 mg/kg with the 
toxicity class 4 indicates that it can be  
safe in low dosages. The ligand map of hit#4  
depicted in figure 2d indicates that it has several 
contacts with residues: Pro 15, Pro 16, Pro 17, 
Asn 18, Leu 24, Ile 32, Ans 49, Asn 50, Lys 63, 
His 65 and Leu 66. Based on the pharmacological 
properties, this ligand can also be introduced as a 




Figure 2 .The ligand map of 4 successive hits, A: hit#1 is in contact with Trp 13, Arg 14, Pro 16, Asn 49, Lys 63, His 65, Leu 66 
and Thr 68, B: hit#2 is in contact with Trp 13, Arg 14, Pro 15, Pro16, Asn 49, Asn 50, Lys 63, His 65 and Leu 66, C: hit#3 is in 
cotact with Arg 14, Pro 15, Pro 16, Asn 18, Asn 49, Lys 63, Glu 64, His 65, Leu 66, Ala 67 and Thr 68 which indicates that this hit 
covers amino acid position 63-68 sequentially and D: hit#4 is contacted with residues: Pro 15, Pro 16, Pro 17, Asn 18, Leu 24, Ile 
32, Ans 49, Asn 50, Lys 63, His 65 and Leu 66 
 
DISCUSSION  
     Ebola virus (EBOV) login needs surface 
glycoprotein (GP) for anchoring and fusion of the 
viral membrane and the host cell. GP1 which is 
accountable for binding to the receptor is on 
target cells. 
Nathan et al reported that a glycoprotein 
construct, which mimics the cathepsin enzyme of 
the EboGP glycan caps and mucin-like domains, 
is able to counteract tetherin. Incorporating these 
outcomes proposes an important role for the 
EboGP glycan cap in tetherin antagonism [30]. 
Jeffrey et al. found the composite of crystal 
structure and Ebola virus GP in its trimeric, pre -
ligation (GP1 + GP2) which is confined to a 
counteracting antibody [31]. The findings of the 
other study provided the the assumption that 
priming of EBOV GP, originally the core of the 
19 kDa, stoutened GP fusion dependent to 
structural varieties thereupon. Supplementary 
results supported that low pH and additional 
endosomal element operate as extensive ligation 
or fusion [32]. In the present study, the 3D 
structure of GP1 was first predicted and after 
structure verifications, a database containing 
100.000 ligands was screened and 4 hits were 
found which could potentially inhibit the viral 
entry by blocking the N-terminal domain of GP1. 
In order to reach high binding affinity poses, the 
virtual screening radius was put in the N-terminal 
domain of GP1. Top successive hits were filtered 
regarding Lipinski rule of 5 and finally 4 hits 
were selected for the further study. 
 
CONCLUSION 
     GP1 from Ebola virus is responsible for host 
cell binding. In this study, 3 new hypothetical 
ligands are introduced which could bind the N-
terminal domain of GP1. Based on the 
pharmacological properties, hit #1, 3 and 4 are 
34 




presented as the new hypothetical drugs against 
GP1. Moreover, hit#1 has previously been 
recorded as nontoxic activity on human cell line 
which makes it an appropriate candidate for 
further in vitro and in vivo studies. 
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